Benefits
Antioxidant Support
NAC boosts glutathione production, a critical antioxidant, helping neutralize free radicals and reduce oxidative stress. This supports overall cellular health. Worth knowing: the studies cited here that actually measured oxidative stress did so in patients, stem cell transplant recipients and men attending a fertility clinic, not in healthy people, so for a general reader this is a well-described mechanism rather than a measured result.
Liver Health and Detoxification
NAC supplies cysteine for glutathione, the pathway the liver uses to neutralize reactive compounds. Be clear about where the strong liver evidence comes from: it is a hospital antidote protocol for acetaminophen poisoning, 140 mg per kilogram of body weight followed by 70 mg per kilogram every four hours under emergency medical care. For a 70 kilogram adult the loading dose alone is close to 10 grams, many times a supplement dose, and none of this is a reason to take NAC alongside paracetamol at home. Nothing cited on this page tested NAC for fatty liver or for everyday liver support.
Respiratory Health
As a mucolytic, NAC breaks the disulfide bonds that make mucus thick, which is a well-established physical effect. The clinical trials were run in patients with diagnosed chronic obstructive pulmonary disease, and the results are genuinely mixed rather than uniformly positive: the 523-patient BRONCUS trial at 600 mg a day concluded that NAC was ineffective for both lung function decline and flare-ups, while the larger PANTHEON trial at 1,200 mg a day did cut flare-ups. Nothing here was measured in healthy people, and cystic fibrosis is a serious inherited disease that no supplement should be presented as addressing.
Mental Health Support
NAC is under active study for mood and for the glutamate signalling thought to sit under compulsive behaviour, and it is worth saying exactly who was studied and what happened. In 75 people already diagnosed with and medicated for bipolar disorder, adding NAC improved depression ratings over 24 weeks, but it did not change time to the next mood episode and the improvement was lost after a four-week washout. In 44 adults with diagnosed obsessive-compulsive disorder, NAC missed its main outcome, and a smaller share of participants responded on NAC (20 percent) than on placebo (27 percent). The material on cocaine and cannabis cravings comes from a narrative review, not from any trial cited here. None of this makes NAC a treatment for a psychiatric condition.
Immune Function
NAC may support immune function through glutathione and through its effect on inflammatory signalling, but the honest position is that no study cited on this page used an immune measure or an infection rate as an outcome. In the one trial here that recorded infections, in stem cell transplant patients, serious infections were reported in 24 percent of the NAC group and 25 percent of the comparison group.
Fertility Benefits
In 120 men attending a clinic for unexplained poor semen quality, oral NAC at 600 mg a day for three months improved semen volume, motility and viscosity compared with placebo, while sperm count and shape did not change. In women with polycystic ovary syndrome, pooled data from eight randomized trials in 910 women show better odds of ovulation and pregnancy than placebo, but NAC did less well than metformin and did not shift insulin, testosterone or body mass index. Both bodies of evidence come from people already diagnosed with a fertility problem, and neither tells you what NAC does for someone who is already fertile.
Mechanism of action
Glutathione Precursor
NAC provides cysteine, a rate-limiting precursor for glutathione synthesis, boosting antioxidant defenses and protecting cells from oxidative damage.
Mucolytic Action
NAC breaks disulfide bonds in mucus proteins, reducing mucus viscosity and improving airway clearance in respiratory conditions like COPD or bronchitis.
Glutamate Modulation
In the brain, NAC regulates glutamate levels by modulating the cystine-glutamate antiporter, potentially reducing excitotoxicity. This is the proposed rationale behind the psychiatric trials described above, not a demonstrated effect in people who are well.
Detoxification
In acetaminophen overdose, NAC replenishes glutathione to neutralize the toxic metabolite NAPQI and prevent liver damage. That is a hospital antidote given at drug doses under medical supervision, which is a different thing from the general detox support a daily capsule is sold for.
Anti-Inflammatory Effects
NAC inhibits pro-inflammatory pathways (e.g., NF-κB) and reduces cytokine production, mitigating inflammation in various conditions.
Clinical trials
Clinical trial in patients with obsessive-compulsive disorder assessing NAC (up to 3 g/day) as augmentation to standard SSRI therapy. (CNS Drugs)
OCD patients on SSRIs.
The trial missed its primary endpoint: total Yale-Brown Obsessive Compulsive Scale scores did not separate from placebo (p=0.39), and a per-protocol analysis did not either (p=0.15). Only the compulsions subscale reached significance, at week 12 and gone again by week 16, and a smaller share of participants responded on NAC (20 percent) than on placebo (27 percent). Not established as therapy. Note: OCD treatment landscape primarily SSRIs at high doses + ERP (exposure response prevention) therapy — NAC adjunctive at most.
Clinical trial at AIIMS, India, in 40 patients with acute ischemic stroke who received intravenous NAC at 150 mg per kilogram of body weight alongside clot-dissolving alteplase. That is a hospital intravenous drug protocol, not oral supplementation. (Sci Rep)
40 acute stroke patients: 19 given intravenous NAC plus alteplase, 21 given alteplase alone.
The trial was designed to test safety, and NAC was safe: no difference in bleeding or adverse events. Neurological scores at 24 hours were better in the NAC arm, but disability and death at three months were no different, and the study was open label with blinded outcome assessors. Note: small trial in single center; modern stroke care emphasizes thrombolysis (alteplase, tenecteplase) and thrombectomy — NAC has no established role in standard stroke care.
Open-label phase 3 trial in patients aged 15 to 60 with acute leukemia undergoing haploidentical stem cell transplantation. 120 patients judged high risk on a bone marrow endothelial cell marker were randomized 2 to 1 to NAC prophylaxis or no prophylaxis, and a further 105 lower-risk patients were followed for comparison. Main outcome: poor graft function or prolonged low platelets at day 60. (BMC Med)
120 high-risk transplant patients randomized to NAC or no prophylaxis, plus 105 lower-risk patients followed for comparison.
Poor graft function or prolonged low platelets at day 60 occurred in 7.5 percent of the NAC group and 22.5 percent of the no-prophylaxis group (hazard ratio 0.317, 95 percent CI 0.113 to 0.890, p=0.021), and reactive oxygen species in marrow cells fell with NAC. This was an open-label trial of 120 randomized patients rather than a large blinded one, and it is supportive care evidence from a hospital transplant ward.
The HIACE study: a 1-year double-blind placebo-controlled trial of NAC 600 mg twice daily in 120 patients with stable COPD at one hospital in Hong Kong. Outcomes: lung function, symptoms, walking distance, quality of life, and flare-up rate.
120 stable COPD patients.
Small airway flow improved (p=0.037), as did airway resistance on forced oscillation, and flare-ups fell from 1.71 to 0.96 per year (p=0.019). Breathlessness scores, quality of life and walking distance did not change, and sputum clearance was never measured. For context, the 1,006-patient PANTHEON trial at the same dose cut flare-ups by 22 percent, but it was funded by an NAC manufacturer, while the 523-patient BRONCUS trial at half the dose found no benefit on either lung function or flare-ups. The inhaled corticosteroid idea comes from a BRONCUS subgroup analysis that its own authors described only as suggestive. NAC appears in some COPD guidelines as an adjunct mucolytic for diagnosed patients.
Ongoing double-blind, placebo-controlled clinical trial (NCT04542161) at Cornell University testing NAC for myalgic encephalomyelitis/chronic fatigue syndrome. (protocol)
ME/CFS patients (ongoing).
Trial ongoing — outcomes pending. Background rationale: NAC may modulate brain glutathione/oxidative stress implicated in ME/CFS pathophysiology. Current ME/CFS treatment is supportive; no established disease-modifying therapy.